Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.44 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21991589 | 0.87 | MAPT (0.49) | ALDH1A1HPGDHTTSMN1; SMN2KMT2A | |
| SCHEMBL21991336 | 0.87 | CYP1A2 (0.50) | ALDH1A1KMT2A | |
| SCHEMBL21991567 | 0.87 | TSHR (0.43) | ALDH1A1TSHRKMT2AMAPT | |
| SCHEMBL21991341 | 0.87 | TSHR (0.45) | ALDH1A1CYP2C9TSHRDRD3SMN1; SMN2 | |
| SCHEMBL21991332 | 0.87 | CYP2C9 (0.46) | ALDH1A1CYP2C9TSHRHPGDMTNR1A | |
| SCHEMBL21991932 | 0.85 | LDHA (0.50) | ALDH1A1CYP2C9TSHRHPGDDRD3 | |
| SCHEMBL21991581 | 0.83 | ALDH1A1 (0.48) | ALDH1A1 | |
| SCHEMBL21991993 | 0.83 | CYP1A2 (0.47) | ALDH1A1KMT2A | |
| SCHEMBL22651641 | 0.83 | ALDH1A1 (0.51) | ALDH1A1CYP2C9TSHRHPGDMTNR1A | |
| SCHEMBL21991940 | 0.81 | HPGD (0.53) | ALDH1A1CYP2C9TSHRHPGDDRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220409566-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-12-29 | — | — | US | disclosed |
| US-20220142961-A1 | CCL5 Inhibitors | LAPKO INC, dba AFECTA PHARMACEUTICALS | 2022-05-12 | — | — | US | disclosed |
| US-11318111-B2 | CCL5 inhibitors | LAPKO INC (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210196665-A1 | CCL5 Inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-07-01 | — | — | US | disclosed |
| US-10940132-B2 | CCL5 inhibitors | AFECTA PHARMACEUTICALS, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200138766-A1 | CCL5 INHIBITORS | LAPKO INC. DBA AFECTA PHARMACEUTICALS | 2020-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142961-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | ALDH1A1 932/4885CYP2C9 1183/4885TSHR 3214/4885 |
| US-20200138766-A1 | CCL5 INHIBITORS | CCL5, CCL11, CCR5 | ALDH1A1 932/4885CYP2C9 1183/4885TSHR 3214/4885 |
| US-20210196665-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | ALDH1A1 932/4885CYP2C9 1183/4885TSHR 3214/4885 |
| US-10940132-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | ALDH1A1 932/4885CYP2C9 1183/4885TSHR 3214/4885 |
| US-11318111-B2 | CCL5 inhibitors | CCL5, CCL11, CCR5 | ALDH1A1 932/4885CYP2C9 1183/4885TSHR 3214/4885 |
| US-20220409566-A1 | CCL5 Inhibitors | CCL5, CCL11, CCR5 | ALDH1A1 932/4885CYP2C9 1183/4885TSHR 3214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.